Statistics Not Every Drug for an Indication Will Make It

Irrefutable Statistics Not Every Drug for an Indication Will Make It 

Since it is well known that not every drug for an indication will make it, why does Wall Street react so swiftly and badly to setbacks In the specific case of Merck and antidepressants, it is for two reasons, the first of which is indirect. 

Since new molecular biological and transgenic approaches have revealed a new group of targets for antidepressants, the substance-P receptor NK-1 (see Box 22.1 for details), antidepressants are still seen as a good business investment. 

Ttuee drug discovery paradigms pointed to monoamingrc targets and to the NK-1 Kceptor to troat major depEssion 

Box 22.1 The Birth of the Lar gest Indication Major Depression 15.2 Billion— cont d 

---